Medicaid Coverage Criteria For CAR-T Often More Restrictive Than Label
Executive Summary
More than 70% of additional coverage criteria for Kymriah and Yescarta are associated with the inclusion or exclusion criteria used in registration trials, according to a study by Rutgers researchers.
You may also be interested in...
New Payment Models For Curative Treatments Have CMS’ Attention, Verma Says
US Centers for Medicare and Medicaid Services administrator Seema Verma discusses solutions for handling the high cost of gene therapy and the Trump administration’s drug pricing agenda in briefing with reporters.
Paying For Gene Therapy: Medicaid Will Be ‘Canary In Coal Mine’
Harvard Pilgrim's Michael Sherman and Cigna's Steve Miller advise gene therapy developers to consider the burden of high cost treatments on Medicaid programs when setting list prices.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.